Latest News by Industry
GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023. Details of the event and replay are as follows:
Conference call details: | |
Date: | May 9, 2023 |
Time: | 8:30 a.m. U.S. Eastern Daylight Time (EDT) |
Dial-in number: | (877) 883-0383 (Domestic) or (412) 902-6506 (International) |
Passcode: | 3370620 |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. EDT, May 9, 2023, until 11:59 p.m. U.S. EDT, May 16, 2023 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 1969560 |
Webcast: | ir.novavax.com/events, until August 7, 2023 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-first-quarter-2023-financial-results-and-operational-highlights-on-may-9-2023-301812543.html
SOURCE Novavax, Inc.